COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Evaluation of Nanomedicine Drug Release and Pharmacokinetics

The NCL has two Technical Services to measure drug release from nanomedicines—ideal for assessing bioequivalence of complex drugs. These assays are available as a service to nanomedicine developers, apart from NCL’s Assay Cascade application process.

The two assays utilize the Stable Isotope Tracer Ultrafiltration Assay (SITUA), and include:

  1. In vitro drug release in human plasma
  2. A pharmacokinetic study in rats

Evaluation of Nanomedicine Drug Release and Pharmacokinetics

The assay uses a stable isotopically labeled version of the drug and a simple ultrafiltration technique, allowing for easy measurement of plasma protein bound, unencapsulated and encapsulated nanomedicine fractions. (J Control Release, 2015, 220(Pt A), 169-174.)

To learn more about the assay, watch this video or download a printable brochure. You can also find more information on NCL's Technical Services page.

Have questions or interested in the service? Contact the NCL team at We'd be happy to have a one-on-one call with your team to discuss the specifics of your formulation and how this assay might be applied.